Shanghai Junshi Biosciences (HKG:1877) said it expects 873 million yuan in 2025 losses, narrowing 32% year on year from a loss of 1.28 billion yuan, according to a Hong Kong bourse filing Friday.
Shares of the drug maker fell nearly 3% in late morning trade Monday.
The company's operating revenue is expected to increase by 28% year on year to 2.50 billion yuan, the firm said.